arsenic has been researched along with tamoxifen in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Diwan, BA; Liu, J; Powell, DA; Waalkes, MP; Ward, JM | 1 |
| Diwan, BA; Liu, J; Waalkes, MP; Ward, JM | 1 |
| Diwan, BA; Liu, J; Waalkes, MP | 1 |
| Fan, Q; Lu, SH; Ma, Z; Wang, F; Wang, L; Wang, R; Wu, X; Yang, J; Zhang, W | 1 |
| Flomenberg, N; Goldberg, A; Howell, A; Ko, YH; Lin, Z; Lisanti, MP; Martinez-Outschoorn, UE; Pavlides, S; Pestell, RG; Sotgia, F; Wang, C | 1 |
| Fan, QX; Wang, F; Wang, LX; Wang, R; Wu, XA; Xu, DF; Zhang, WJ | 1 |
| Adachi, K; Honma, Y; Kawakami, K; Miyake, T; Suzumiya, J; Takahashi, T | 1 |
8 other study(ies) available for arsenic and tamoxifen
| Article | Year |
|---|---|
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment.
Topics: Animals; Arsenic; Body Weight; Diethylstilbestrol; Drinking; Drug Synergism; Estrogen Receptor alpha; Female; Gene Expression; Genital Neoplasms, Female; Kidney Neoplasms; Maternal-Fetal Exchange; Mice; Pregnancy; Prenatal Exposure Delayed Effects; Tamoxifen; Urinary Bladder Neoplasms; Uterus | 2006 |
Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen.
Topics: Animals; Arsenic; Diethylstilbestrol; Drug Synergism; Estrogen Receptor alpha; Estrogens, Non-Steroidal; Female; Liver Neoplasms; Male; Maternal-Fetal Exchange; Mice; Mice, Inbred Strains; Pregnancy; Prenatal Exposure Delayed Effects; Selective Estrogen Receptor Modulators; Tamoxifen; Urinary Bladder Neoplasms | 2006 |
Transplacental arsenic carcinogenesis in mice.
Topics: Animals; Anticarcinogenic Agents; Arsenic; Arsenicals; Carcinogens; Carcinoma, Transitional Cell; Data Interpretation, Statistical; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Synergism; Estrogens; Female; Gene Expression Regulation, Neoplastic; Male; Maternal-Fetal Exchange; Mice; Mice, Inbred C3H; Neoplasms; Pregnancy; Prenatal Exposure Delayed Effects; Signal Transduction; Skin Neoplasms; Tamoxifen; Tetradecanoylphorbol Acetate; Urinary Bladder Neoplasms | 2007 |
Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Tamoxifen; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fibroblasts; Fulvestrant; Humans; Hypoglycemic Agents; Intracellular Signaling Peptides and Proteins; Ketone Bodies; Lactic Acid; Metformin; Mitochondria; Oxides; Phosphoric Monoester Hydrolases; Poly(ADP-ribose) Polymerase Inhibitors; Tamoxifen; Tumor Microenvironment | 2011 |
[Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; RNA, Messenger; Tamoxifen; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells.
Topics: Animals; Anthracyclines; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; CD11b Antigen; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred BALB C; Middle Aged; Oxides; Tamoxifen; Tretinoin | 2016 |